Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Toxoplasmosis serology

PreclinicalBiologic

UUniversity Hospital, Grenoble

Toxoplasmosis serology is one of 2 biologic programs targeting Toxoplasmosis. It is currently in Preclinical.

1

Indications

1

Total Trials

0

Active Trials

1

Competitors

Pipeline

Status by Indication[3][1]

Indication

ToxoplasmosisActive, not recruiting

ToxoplasmosisPreclinical

Active, not recruiting

Competition

Competitive Landscape

4 competitors in Toxoplasmosis

#DrugCompanyPhaseTrials

Daraprim

FFondazione Matilde Tettamanti Menotti De Marchi Onlus

Toxoplasmosis serology

UUniversity Hospital, Grenoble

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Toxoplasmosis1 trial

Evaluation of Biological Biomarkers Diagnostic of Toxoplasmosis Uveitis

Completed·UUniversity Hospital, Grenoble·N/A·NCT02843438·72 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Toxoplasmosis serology. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Toxoplasmosis serology compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Toxoplasmosis serology. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University Hospital, Grenoble company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Preclinical[1]
Company: UUniversity Hospital, Grenoble

Related News